Merck & Co gambles on generic biologics
This article was originally published in Scrip
Executive Summary
Merck & Co is to break into generic biologics and expand into emerging markets. The firm will diversify R&D and invest in key Asian markets as it seeks growth amid concerns about its contracting bottom line.